Biomerica (BMRA) Net Cash Flow (2010 - 2026)

Biomerica (BMRA) has 17 years of Net Cash Flow data on file, last reported at -$1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 273.07% year-over-year to -$1.2 million; the trailing twelve-month figure through Feb 2026 stood at -$1.7 million (up 31.96% YoY), and the FY2025 full-year result was -$1.8 million, up 68.2% from the prior year.
• Net Cash Flow eased to -$1.2 million in Q1 2026, from -$509000.0 in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $6.4 million in Q2 2023 to a low of -$4.2 million in Q2 2022.
• A 5-year average of -$356659.7 and a median of -$854000.0 in 2023 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow surged 833.68% in 2022 and plunged 1115.79% in 2023, its largest moves.
• Tracing BMRA's Net Cash Flow over 5 years: stood at -$1.0 million in 2022, then increased by 14.6% to -$854000.0 in 2023, then advanced by 7.38% to -$791000.0 in 2024, then surged by 35.65% to -$509000.0 in 2025, then plunged by 133.6% to -$1.2 million in 2026.
• Business Quant data shows BMRA's Net Cash Flow at -$1.2 million in Q1 2026, -$509000.0 in Q4 2025, and $652000.0 in Q3 2025.